GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.
Motso A, Pelcman B, Kalinovich A, Kahlous NA, Bokhari MH, Dehvari N, Halleskog C, Waara E, de Jong J, Cheesman E, Kallenberg C, Yakala GK, Murad P, Wetterdal E, Andersson P, van Beek S, Sandström A, Alleluia DN, Talamonti E, Youhanna S, Sabatier P, Koenig C, Willems S, Kemas AM, Hutchinson DS, Ham S, Grätz L, Voss J, Marchan-Alvarez JG, Priede M, Jaunsleine K, Spura J, Kovada V, Supe L, Stoddart LA, Holliday ND, Newton PT, Pillon NJ, Schulte G, Summers RJ, Mutule I, Suna E, Olsen JV, Molenaar P, Carlsson J, Lauschke VM, Wright SC, Bengtsson T.
Motso A, et al. Among authors: pillon nj.
Cell. 2025 Sep 18;188(19):5142-5156.e23. doi: 10.1016/j.cell.2025.05.042. Epub 2025 Jun 23.
Cell. 2025.
PMID: 40555230
Free article.